Planview Reports Record Q2 and H1 2023, Continues Momentum Amid Challenging Economic Landscape
20.7.2023 18:18:00 EEST | Business Wire | Press release
Planview, the leading platform for digital connected work from portfolio planning to delivery, announced today record annual recurring revenue (ARR) and bookings in Q2, continuing strong momentum and growth in 2023. ACV Bookings for Q2 and the first half of the year were at a record high approaching 30% growth year-over-year (YoY), driven by both new customer additions and customer expansions across financial services, automotive, and healthcare. At the close of H1 2023, Planview is outpacing its forecasts on several key measures, including bookings, retention, and ARR this year. These results are driven by significant demand from customers who require data-driven insights to effectively prioritize initiatives, allocate capital and utilize resources across digital transformation efforts.
“The macroenvironment continues to pose challenges for digital transformation efforts in companies around the world. Organizations are faced with inflation, changing customer expectations, and more conservative budgets,” said Razat Gaurav, CEO at Planview. “At the same time, they must continue to drive forward transformation initiatives to adapt and achieve key business outcomes. Planview’s connected solution is uniquely positioned to give leaders and organizations the data-driven alignment, transparency, and visibility to make critical prioritization decisions, enabling companies to increase productivity, improve time-to-market, and de-risk strategic bets.”
H1 2023 Highlights
- Strong ACV bookings growth for the first half of 2023, approaching 30% growth YoY
- Significant improvements to Retention through first half of 2023, +100bps improvement to Net Retention YoY
- Recurring Revenue grew 13% during the first half of 2023 YoY
- Added over 126 net new customers
- Grew total active users for University of Planview by 29% quarter-over-quarter
Strong New Logo and Customer Momentum
Planview’s outperformance and profitable growth has been driven by new customer wins and expansions. New and notable customers who partnered or significantly expanded their footprint with Planview include AT&T, Axcelis Technologies, Bausch + Lomb, Baylor Scott & White Health, CellCarta, ChristianaCare, Commonwealth Bank of Australia, Corewell Health, Ecopetrol Group, Foodstuffs, Ford Motor Company, Inland Empire Health Plan, LandSure Systems, Mitsubishi UFJ Financial Group, New York Life Insurance Company, Omnicell, OneSavings Bank, PagoNxt, Pladis Global, Schaeffler Group, Schwab, Sherwin-Williams, Sun Life Financial, Transport for NSW, Tronox Holdings, Vanguard Group, Vonage, and Voya.
Industry Leadership & Product Innovation
Key milestones that support continued customer success and the company's strong growth:
- Showcased new Generative AI based assistant at the Reuters Momentum AI Summit.
- Released the landmark 2023 Project to Product State of the Industry Report, which revealed that 40% of Digital Innovation work is being wasted today.
- Recognized for the second consecutive year as a leader in the 2023 Gartner® Magic Quadrant™ for Strategic Portfolio Management. The company was positioned furthest for Completeness of Vision.
- Expanded its global footprint with growing teams in North America, EMEA, Israel and India, with a focus on Artificial Intelligence (AI), Data Science, R&D, Premium Support, Managed Services, InfoSec, and Partners/Strategic Alliances.
- Increased its global partner ecosystem with the additions of UiPath and NTT Data, focused on delivering Value Stream Management capabilities.
- Dramatically expanded its partnership with AWS, including achievement of AWS ISV Accelerate Program membership and the launch of five Planview solutions in the AWS Marketplace.
- Increased in monthly active users by 15% YoY for leading products.
Planview is continuing to invest heavily in product innovation, customer success and go-to-market, building a foundation for continued customer satisfaction and growth in 2023 and beyond.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720450990/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom